Literature DB >> 1738989

Economic issues in screening mammography.

R A Clark1.   

Abstract

The issues surrounding screening mammography present apparent conflicts: conflicting guidelines for screening; an oversupply of facilities, yet inadequate access to mammography for some groups of women; increased medicolegal vulnerability as participation in screening is promoted; disparate results from studies of cost-effectiveness; wide variations in delivery modes and practice patterns of facilities, yet an evolution toward a single set price for mammography by payers for screening. This review does not claim to offer solutions to these conflicts, rather it attempts to carry forward a discussion of the issues. With these conflicts, screening mammography may be only a microcosm of similar economic issues in general health care delivery. Our health care system has room for variety, if access and quality are improved at an affordable cost. Screening for breast cancer with mammography will not reach its full potential to reduce mortality until many of these issues can be resolved.

Entities:  

Mesh:

Year:  1992        PMID: 1738989     DOI: 10.2214/ajr.158.3.1738989

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  3 in total

1.  An economic view of high compliance as a screening objective.

Authors:  D J Torgerson; C Donaldson
Journal:  BMJ       Date:  1994-01-08

2.  Comparison of charges related to radiotherapy for soft-tissue sarcomas treated by preoperative external-beam irradiation versus interstitial implantation.

Authors:  N A Janjan; A W Yasko; G P Reece; M J Miller; J A Murray; M I Ross; M M Romsdahl; M J Oswald; T G Ochran; R E Pollock
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

3.  Cost effectiveness of breast cancer screening using mammography; a systematic review.

Authors:  Arash Rashidian; Eshagh Barfar; Hamed Hosseini; Shirin Nosratnejad; Esmat Barooti
Journal:  Iran J Public Health       Date:  2013-04-01       Impact factor: 1.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.